Patient characteristics from the E2408 validation study
| . | Overall (N = 249) n (%) . |
|---|---|
| Age, years | |
| ≤60 | 124 (49.8) |
| >60 | 125 (50.2) |
| Stage | |
| II | 8 (3.2) |
| IIE | 7 (2.8) |
| III | 40 (16.1) |
| IIIE | 20 (8.0) |
| IV | 174 (69.9) |
| Longest diameter of any lymph node | |
| ≤6 cm | 125 (50.2) |
| >6 cm | 124 (49.8) |
| Hemoglobin, g/dL | |
| ≤12 | 185 (74.3) |
| <12 | 64 (25.7) |
| Bone marrow involvement (biopsy) | |
| No | 101 (41.1) |
| Yes | 145 (58.9) |
| Missing | 3 |
| Elevated β2-microglobulin | |
| No | 81 (33.2) |
| Yes | 163 (66.8) |
| Missing | 5 |
| No. of EN sites on PET | |
| 0-1 | 164 (65.9) |
| ≥2 | 85 (34.1) |
| Osseous involvement on PET | |
| No | 102 (41.0) |
| Yes | 147 (59.0) |
| Skin or soft tissue involvement PET | |
| No | 142 (57.0) |
| Yes | 107 (43.0) |
| Spleen involvement by PET | |
| No | 100 (40.5) |
| Yes | 147 (59.5) |
| Missing | 2 |
| Elevated LDH level | |
| No | 174 (69.9) |
| Yes | 75 (30.1) |
| First-line treatment | |
| BR arm A∗ | 55 (22.1) |
| BVR arm B | 81 (32.5) |
| BR arm C | 113 (45.4) |
| FLIP2: no. of factors | |
| 0 | 11 (4.4) |
| 1-2 | 107 (43.0) |
| 3-5 | 123 (49.4) |
| Missing | 8 |
| PET-based score: no. of factors | |
| 0-1 | 64 (25.7) |
| 2-3 | 101 (40.6) |
| 4-6 | 79 (31.7) |
| Missing | 5 |
| . | Overall (N = 249) n (%) . |
|---|---|
| Age, years | |
| ≤60 | 124 (49.8) |
| >60 | 125 (50.2) |
| Stage | |
| II | 8 (3.2) |
| IIE | 7 (2.8) |
| III | 40 (16.1) |
| IIIE | 20 (8.0) |
| IV | 174 (69.9) |
| Longest diameter of any lymph node | |
| ≤6 cm | 125 (50.2) |
| >6 cm | 124 (49.8) |
| Hemoglobin, g/dL | |
| ≤12 | 185 (74.3) |
| <12 | 64 (25.7) |
| Bone marrow involvement (biopsy) | |
| No | 101 (41.1) |
| Yes | 145 (58.9) |
| Missing | 3 |
| Elevated β2-microglobulin | |
| No | 81 (33.2) |
| Yes | 163 (66.8) |
| Missing | 5 |
| No. of EN sites on PET | |
| 0-1 | 164 (65.9) |
| ≥2 | 85 (34.1) |
| Osseous involvement on PET | |
| No | 102 (41.0) |
| Yes | 147 (59.0) |
| Skin or soft tissue involvement PET | |
| No | 142 (57.0) |
| Yes | 107 (43.0) |
| Spleen involvement by PET | |
| No | 100 (40.5) |
| Yes | 147 (59.5) |
| Missing | 2 |
| Elevated LDH level | |
| No | 174 (69.9) |
| Yes | 75 (30.1) |
| First-line treatment | |
| BR arm A∗ | 55 (22.1) |
| BVR arm B | 81 (32.5) |
| BR arm C | 113 (45.4) |
| FLIP2: no. of factors | |
| 0 | 11 (4.4) |
| 1-2 | 107 (43.0) |
| 3-5 | 123 (49.4) |
| Missing | 8 |
| PET-based score: no. of factors | |
| 0-1 | 64 (25.7) |
| 2-3 | 101 (40.6) |
| 4-6 | 79 (31.7) |
| Missing | 5 |
PET-based score factors: age, longest diameter of any lymph node, hemoglobin, elevated β2-microglobulin, number of EN sites on PET, and skin or soft tissue involvement on PET.
BR, bendamustine-rituximab; BVR, bendamustine-bortezomib-rituximab; LDH, lactate dehydrogenase.
BR arm A, BR induction followed by 2-year rituximab maintenance; BR arm B, BVR with rituximab maintenance; BR arm C, BR followed by lenalidomide (1 year) with rituximab maintenance.